Oppenheimer set a $5.00 price objective on VolitionRX (NYSEAMERICAN:VNRX) in a research report report published on Friday morning. The brokerage currently has a buy rating on the medical research company’s stock.
VNRX traded up $0.03 on Friday, reaching $2.73. The stock had a trading volume of 15,304 shares, compared to its average volume of 108,530. VolitionRX has a fifty-two week low of $1.44 and a fifty-two week high of $4.00.
VolitionRX (NYSEAMERICAN:VNRX) last issued its earnings results on Wednesday, November 7th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.14).
A hedge fund recently bought a new stake in VolitionRX stock. Leisure Capital Management purchased a new stake in VolitionRX Ltd (NYSEAMERICAN:VNRX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 72,479 shares of the medical research company’s stock, valued at approximately $188,000. Leisure Capital Management owned about 0.21% of VolitionRX at the end of the most recent quarter.
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
Featured Article: Bond
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.